Close Menu

NEW YORK – Myriad Genetics announced that it will file a supplementary premarket approval application with the US Food and Drug Administration for its BRACAnalysis CDx to be used to identify which metastatic, castration-resistant prostate cancer patients have germline BRCA mutations and may benefit from treatment with olaparib (AstraZeneca and Merck’s Lynparza). 

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Wall Street Journal looks into FamilyTreeDNA's handling of genetic genealogy searches by law enforcement.

In a point-counterpoint in the Boston Globe, researchers discuss the potential of gene editing to prevent Lyme disease, but also the pitfalls of doing so.

MIT's Technology Review reports that researchers hope to develop a CRISPR-based pain therapy.

In Science this week: atlas of malaria parasites' gene expression across their life cycles, and more.